2009 (118)
2010 (83)
2011 (69)
2014 (120)
2019 (209)
2024 (304)
2025 (291)
Moderna has recently seen positive developments, including an upgrade in its Relative Strength Rating and expectations for$1.9 billionin revenue for 2025. However, challenges remain with declining earnings and sales growth, alongside ongoing legal issues regarding patent infringements in mRNA technology.